Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$59.90 -2.0%	$61.57	$43.70 ▼ $86.53	$1.91B	-1.44	45,185 shs	57,772 shs
DNLI Denali Therapeutics	$14.49 +0.3%	$14.39	$10.57 ▼ $33.33	$2.11B	1.32	1.12 million shs	913,543 shs
KURA Kura Oncology	$5.73 -1.2%	$6.18	$5.41 ▼ $23.48	$496.05M	0.4	1.24 million shs	817,786 shs
RXRX Recursion Pharmaceuticals	$5.40 +4.7%	$4.90	$3.79 ▼ $12.36	$2.20B	0.84	15.60 million shs	21.38 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	+2.38%	+1.23%	+0.16%	-8.60%	+25.98%
DNLI Denali Therapeutics	+0.35%	+2.56%	+7.68%	+1.76%	-35.46%
KURA Kura Oncology	-3.01%	-4.29%	+2.84%	-18.77%	-71.69%
RXRX Recursion Pharmaceuticals	-1.15%	+0.98%	+26.47%	-13.57%	-44.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLTE Belite Bio	2.4475 of 5 stars	3.5	3.0	0.0	2.5	0.8	0.6
DNLI Denali Therapeutics	4.4125 of 5 stars	4.5	1.0	4.7	2.7	2.5	0.0
KURA Kura Oncology	4.2971 of 5 stars	4.4	1.0	4.7	2.6	0.8	0.6
RXRX Recursion Pharmaceuticals	1.8793 of 5 stars	3.2	1.0	0.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	3.00	Buy	$96.67	61.38% Upside
DNLI Denali Therapeutics	3.06	Buy	$33.71	132.67% Upside
KURA Kura Oncology	2.86	Moderate Buy	$24.50	327.57% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	29.63% Upside

Current Analyst Ratings Breakdown

Latest KURA, DNLI, RXRX, and BLTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/20/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$36.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
6/4/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/19/2025	KURA Kura Oncology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/15/2025	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/15/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/7/2025	DNLI Denali Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $32.00

(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$4.72 per share	N/A
DNLI Denali Therapeutics	$330.53M	6.37	N/A	N/A	$8.53 per share	1.70
KURA Kura Oncology	$53.88M	9.21	N/A	N/A	$5.32 per share	1.08
RXRX Recursion Pharmaceuticals	$58.84M	37.31	N/A	N/A	$2.61 per share	2.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$36.14M	-$1.36	N/A	N/A	N/A	N/A	-32.07%	-30.91%	8/8/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	7/30/2025 (Estimated)
KURA Kura Oncology	-$173.98M	-$2.10	N/A	N/A	N/A	N/A	-43.62%	-29.13%	8/6/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.77	N/A	N/A	N/A	-961.32%	-74.70%	-54.02%	8/6/2025 (Estimated)

Latest KURA, DNLI, RXRX, and BLTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
5/5/2025	Q1 2025	RXRX Recursion Pharmaceuticals	-$0.44	-$0.50	-$0.06	-$0.50	$18.12 million	$14.75 million
5/1/2025	Q1 2025	KURA Kura Oncology	-$0.51	-$0.66	-$0.15	-$0.66	$39.08 million	$14.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	24.31	24.31
DNLI Denali Therapeutics	N/A	9.56	9.56
KURA Kura Oncology	0.02	8.07	8.07
RXRX Recursion Pharmaceuticals	0.02	4.11	4.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
DNLI Denali Therapeutics	92.92%
KURA Kura Oncology	N/A
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
DNLI Denali Therapeutics	12.50%
KURA Kura Oncology	6.40%
RXRX Recursion Pharmaceuticals	8.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
KURA Kura Oncology	130	86.57 million	81.03 million	Optionable
RXRX Recursion Pharmaceuticals	400	406.49 million	372.23 million	Optionable

KURA, DNLI, RXRX, and BLTE Headlines

Recent News About These Companies

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 1.2% - Time to Sell?

4 hours ago | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down - Here's What Happened

June 26 at 11:54 AM | marketbeat.com

Morgan Stanley Trims Recursion (RXRX) Price Target, Maintains Equal Weight Rating

June 26 at 2:06 AM | msn.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.9% - What's Next?

June 25 at 2:21 PM | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 7.3% - Time to Buy?

June 24 at 2:17 PM | marketbeat.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Rating of "Hold" from Analysts

June 24 at 2:41 AM | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.1% - What's Next?

June 23 at 2:56 PM | marketbeat.com

Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors

June 20, 2025 | zacks.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Position Boosted by SG Americas Securities LLC

June 20, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 5.6% - Here's What Happened

June 19, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.5% - Time to Buy?

June 18, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Given New $5.00 Price Target at Morgan Stanley

June 17, 2025 | americanbankingnews.com

Expert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 Analysts

June 17, 2025 | benzinga.com

Morgan Stanley Lowers Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target to $5.00

June 16, 2025 | marketbeat.com

Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?

June 16, 2025 | fool.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 2.2% - Here's Why

June 13, 2025 | marketbeat.com

Leerink Partnrs Has Positive Estimate for RXRX Q2 Earnings

June 13, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 2.4% - Should You Sell?

June 12, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 4% Higher - Should You Buy?

June 11, 2025 | marketbeat.com

Insmed surges on lung drug data; Recursion cuts staff

June 11, 2025 | biopharmadive.comB

AI-Focused Recursion Pharmaceuticals Stock Jumped 31% Last Week; Here's Why

June 11, 2025 | talkmarkets.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA, DNLI, RXRX, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

$59.90 -1.20 (-1.96%)

Closing price 04:00 PM Eastern

Extended Trading

$60.29 +0.39 (+0.65%)

As of 04:04 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Denali Therapeutics NASDAQ:DNLI

$14.49 +0.04 (+0.28%)

Closing price 04:00 PM Eastern

Extended Trading

$14.49 0.00 (0.00%)

As of 06:25 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Kura Oncology NASDAQ:KURA

$5.73 -0.07 (-1.21%)

Closing price 04:00 PM Eastern

Extended Trading

$5.78 +0.05 (+0.96%)

As of 06:24 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Recursion Pharmaceuticals NASDAQ:RXRX

$5.40 +0.24 (+4.65%)

Closing price 04:00 PM Eastern

Extended Trading

$5.38 -0.03 (-0.46%)

As of 06:28 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time